]>
IRCT2016010411991N3 IRCT 2016-01-22 Vice chancellor for research,Kermanshah University of Medical Sciences Effect of metformin, pioglitazone and vitaminE E in patients with non-alcoholic fatty liver disease Compare the therapeutic effect of metformin, pioglitazone and vitaminE E in patients with non-alcoholic fatty liver disease 2009-05-22 anticipated 93 Complete https://irct.ir/trial/12159 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. N/A non-alcoholic fatty liver disease. Intervention 1: Intervention group: metformin2 gr daily,orally for12 weeks. Intervention 2: Intervention group: Pioglitazone30 mg dialy, orally for12 weeks. Intervention 3: Intervention group: vitamin E 800 IU daily, orally for 12 weeks.
public Karoon Shahebrahimi
Emam Reza hospital, Sorkhelijeh boulevard, Kermanshah
Kermanshah Iran (Islamic Republic of) +98 83 3427 6301 kshahebrahimi@gmail.com Kermanshah University of Medical Sciences scientific Karoon Shahebrahimi
Emam Reza hospital, Sorghelijeh, Kermanshah
Kermanshah Iran (Islamic Republic of) +98 83 3427 6301 kshahebrahimi@gmail.com Kermanshah University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: patients with non-alcoholic fatty liver disease according to sonographic findings; Having age between 17 to 50 years; Having negative serology of viral hepatitis; Willingness to participate in the study. Exclusion criteriain: having obvious presentations of hepatic diseases; history of jaundice; taking steroids; alcohol drinking; diabetes; pregnancy; hypothyroidism; renal failure. 18 years 75 years Both K76.0 Fatty (change of) liver, not elsewhere classified Treatment - Drugs Treatment - Drugs Treatment - Drugs Intervention group: metformin2 gr daily,orally for12 weeks Intervention group: Pioglitazone30 mg dialy, orally for12 weeks Intervention group: vitamin E 800 IU daily, orally for 12 weeks. Severity of fatty liver. Timepoint: before and 12 weeks after the interventions. Method of measurement: according to echogenicity of the liver and its comparison with the adjacent kidney, and also comparison with echogenicity of the spleen, and the view of diaphragm and perivascular region of the intrahepatic vessels. Serum level of liver function tests (AST, ALT, Alkp). Timepoint: before and 12 weeks after the interventions. Method of measurement: (IU/l) by diagnostic laboratory kits (Pars Azmoon, Iran) and the auto analyzer (Hitachi 902). Body mass index(BMI). Timepoint: before and 12 weeks after the interventions. Method of measurement: (Kg/m2). Insulin resistance index(HOMA-IR). Timepoint: before and 12 weeks after the interventions. Method of measurement: [fasting glucose (mg/dl) × insulin (µU/ml)]/ 405. Fasting blood sugar. Timepoint: before and 12 weeks after the interventions. Method of measurement: mg/dlby diagnostic laboratory kits (Pars Azmoon, Iran) and the auto analyzer (Hitachi 902). Serum level of insulin. Timepoint: before and 12 weeks after the interventions. Method of measurement: (µu/ml) by Monobind ELISA kit (Monobind, USA). Vice chancellor for research,Kermanshah University of Medical Sciences Approved 2009-05-26 Ethics committee of Kermanshah University of Medical Sciences Kermanshah Univesity of Medical Sciences, Shahid Beheshti Blvd.,Kermanshah. Kermanshah Iran (Islamic Republic of)